Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion
Abstract
:1. Introduction
2. Materials and Methods
2.1. Selection of Case and Control Groups for Analysis
2.2. Selection of Genes Associated with ETV4 Expression
2.3. Pathway Analysis
2.4. Therapeutic Targets and Candidate Drugs
2.5. Statistical Analysis and Visualization
3. Results
3.1. Comparison of Patient Characteristics
3.2. Genes Associated in ETV4-Fusion-Positive Prostate Cancer
3.3. Cellular Signaling Pathways Associated with ETV4-Fusion-Positive Prostate Cancer
3.4. Identifying Therapeutic Targets and Potential Actionable Drugs
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Kumar-Sinha, C.; Tomlins, S.A.; Chinnaiyan, A.M. Recurrent Gene Fusions in Prostate Cancer. Nat. Rev. Cancer 2008, 8, 497–511. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tomlins, S.A.; Rhodes, D.R.; Perner, S.; Dhanasekaran, S.M.; Mehra, R.; Sun, X.-W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R.; et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science 2005, 310, 644–648. [Google Scholar] [CrossRef] [PubMed]
- Tomlins, S.A.; Bjartell, A.; Chinnaiyan, A.M.; Jenster, G.; Nam, R.K.; Rubin, M.A.; Schalken, J.A. ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. Eur. Urol. 2009, 56, 275–286. [Google Scholar] [CrossRef]
- Scaravilli, M.; Koivukoski, S.; Latonen, L. Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer. Front. Cell Dev. Biol. 2021, 9, 623809. [Google Scholar] [CrossRef]
- Tomlins, S.A.; Mehra, R.; Rhodes, D.R.; Smith, L.R.; Roulston, D.; Helgeson, B.E.; Cao, X.; Wei, J.T.; Rubin, M.A.; Shah, R.B.; et al. TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer. Cancer Res. 2006, 66, 3396–3400. [Google Scholar] [CrossRef] [Green Version]
- Yun, J.W.; Yang, L.; Park, H.-Y.; Lee, C.-W.; Cha, H.; Shin, H.-T.; Noh, K.-W.; Choi, Y.-L.; Park, W.-Y.; Park, P.J. Dysregulation of Cancer Genes by Recurrent Intergenic Fusions. Genome Biol. 2020, 21, 166. [Google Scholar] [CrossRef]
- Pellecchia, A.; Pescucci, C.; De Lorenzo, E.; Luceri, C.; Passaro, N.; Sica, M.; Notaro, R.; De Angioletti, M. Overexpression of ETV4 Is Oncogenic in Prostate Cells through Promotion of Both Cell Proliferation and Epithelial to Mesenchymal Transition. Oncogenesis 2012, 1, e20. [Google Scholar] [CrossRef] [Green Version]
- Aytes, A.; Mitrofanova, A.; Kinkade, C.W.; Lefebvre, C.; Lei, M.; Phelan, V.; LeKaye, H.C.; Koutcher, J.A.; Cardiff, R.D.; Califano, A.; et al. ETV4 Promotes Metastasis in Response to Activation of PI3-Kinase and Ras Signaling in a Mouse Model of Advanced Prostate Cancer. Proc. Natl. Acad. Sci. USA 2013, 110, E3506–E3515. [Google Scholar] [CrossRef] [Green Version]
- Abeshouse, A.; Ahn, J.; Akbani, R.; Ally, A.; Amin, S.; Andry, C.D.; Annala, M.; Aprikian, A.; Armenia, J.; Arora, A.; et al. The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015, 163, 1011–1025. [Google Scholar] [CrossRef]
- Lever, J.; Zhao, E.Y.; Grewal, J.; Jones, M.R.; Jones, S.J.M. CancerMine: A Literature-Mined Resource for Drivers, Oncogenes and Tumor Suppressors in Cancer. Nat. Methods 2019, 16, 505–507. [Google Scholar] [CrossRef] [PubMed]
- Gu, Z.; Eils, R.; Schlesner, M. Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data. Bioinformatics 2016, 32, 2847–2849. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 2003, 13, 2498–2504. [Google Scholar] [CrossRef] [PubMed]
- Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer|Clinical Cancer Research|American Association for Cancer Research. Available online: https://aacrjournals.org/clincancerres/article/23/7/1829/80365/Pan-Cancer-Analysis-of-the-Mediator-Complex (accessed on 9 July 2022).
- Sen, A.; Castro, I.D.; DeFranco, D.B.; Deng, F.-M.; Melamed, J.; Kapur, P.; Raj, G.V.; Rossi, R.; Hammes, S.R. Paxillin Mediates Extranuclear and Intranuclear Signaling in Prostate Cancer Proliferation. J. Clin. Investig. 2012, 122, 2469–2481. [Google Scholar] [CrossRef]
- Chen, D.; Wang, Z.; Ren, C.; Zeng, Z.; Wang, D.; Luo, H.; Wang, F.; Qiu, M.; Bai, L.; Zhang, D.; et al. Abnormal Expression of Paxillin Correlates with Tumor Progression and Poor Survival in Patients with Gastric Cancer. J. Transl. Med. 2013, 11, 277. [Google Scholar] [CrossRef] [Green Version]
- Liu, Q.; Wang, J.; Tang, M.; Chen, L.; Qi, X.; Li, J.; Yu, J.; Qiu, H.; Wang, Y. The Overexpression of PXN Promotes Tumor Progression and Leads to Radioresistance in Cervical Cancer. Future Oncol. 2018, 14, 241–253. [Google Scholar] [CrossRef]
- Hollenhorst, P.C.; Paul, L.; Ferris, M.W.; Graves, B.J. The ETS Gene ETV4 Is Required for Anchorage-Independent Growth and a Cell Proliferation Gene Expression Program in PC3 Prostate Cells. Genes Cancer 2010, 1, 1044–1052. [Google Scholar] [CrossRef]
- Lonergan, P.E.; Tindall, D.J. Androgen Receptor Signaling in Prostate Cancer Development and Progression. J. Carcinog. 2011, 10, 20. [Google Scholar] [CrossRef]
- Chen, Y.; Clegg, N.J.; Scher, H.I. Anti-Androgens and Androgen-Depleting Therapies in Prostate Cancer: New Agents for an Established Target. Lancet Oncol. 2009, 10, 981–991. [Google Scholar] [CrossRef] [Green Version]
- Clegg, N.J.; Wongvipat, J.; Joseph, J.D.; Tran, C.; Ouk, S.; Dilhas, A.; Chen, Y.; Grillot, K.; Bischoff, E.D.; Cai, L.; et al. ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment. Cancer Res. 2012, 72, 1494–1503. [Google Scholar] [CrossRef]
- Yun, J.W.; Lee, S.; Chun, S.; Lee, K.W.; Kim, J.; Kim, H.S. Comprehensive Analysis of Oncogenic Signatures and Consequent Repurposed Drugs in TMPRSS2:ERG Fusion-positive Prostate Cancer. Clin. Transl. Med. 2021, 11, e420. [Google Scholar] [CrossRef] [PubMed]
- Graff, R.E.; Pettersson, A.; Lis, R.T.; DuPre, N.; Jordahl, K.M.; Nuttall, E.; Rider, J.R.; Fiorentino, M.; Sesso, H.D.; Kenfield, S.A.; et al. The TMPRSS2:ERG Fusion and Response to Androgen Deprivation Therapy for Prostate Cancer. Prostate 2015, 75, 897–906. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crawford, E.D. Hormonal Therapy in Prostate Cancer: Historical Approaches. Rev. Urol. 2004, 6, S3–S11. [Google Scholar] [PubMed]
- Flavin, R.; Zadra, G.; Loda, M. Metabolic Alterations and Targeted Therapies in Prostate Cancer. J. Pathol. 2011, 223, 284–295. [Google Scholar] [CrossRef] [Green Version]
- Cutruzzolà, F.; Giardina, G.; Marani, M.; Macone, A.; Paiardini, A.; Rinaldo, S.; Paone, A. Glucose Metabolism in the Progression of Prostate Cancer. Front. Physiol. 2017, 8, 97. [Google Scholar] [CrossRef] [Green Version]
- Wu, X.; Daniels, G.; Lee, P.; Monaco, M.E. Lipid Metabolism in Prostate Cancer. Am. J. Clin. Exp. Urol. 2014, 2, 111–120. [Google Scholar]
- Li, X.; Wu, K.; Fan, D. CIAPIN1 as a Therapeutic Target in Cancer. Expert Opin. Ther. Targets 2010, 14, 603–610. [Google Scholar] [CrossRef]
- Wang, C.Y.; Mayo, M.W.; Baldwin, A.S. TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-KappaB. Science 1996, 274, 784–787. [Google Scholar] [CrossRef]
- De Bono, J.; Mateo, J.; Fizazi, K.; Saad, F.; Shore, N.; Sandhu, S.; Chi, K.N.; Sartor, O.; Agarwal, N.; Olmos, D.; et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2020, 382, 2091–2102. [Google Scholar] [CrossRef]
- Wen, L.; Zhang, X.; Zhang, J.; Chen, S.; Ma, Y.; Hu, J.; Yue, T.; Wang, J.; Zhu, J.; Wu, T.; et al. Paxillin Knockdown Suppresses Metastasis and Epithelial-mesenchymal Transition in Colorectal Cancer via the ERK Signalling Pathway. Oncol. Rep. 2020, 44, 1105–1115. [Google Scholar] [CrossRef]
- Gu, H.; Wen, J. Abnormal Level of Paxillin in Cervical Cancer Cells Is Involved in Tumor Progression and Invasion. Acta Biochim. Pol. 2021, 68, 49–53. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Xu, D.; Xu, X.; Xue, Q.; Gao, X.; Tang, C. MiR-216b Regulates the Tumorigenesis of Gastric Cancer by Targeting PXN. Pathol. Res. Pract. 2021, 218, 153325. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, N.; Minemura, C.; Asai, S.; Kikkawa, N.; Kinoshita, T.; Oshima, S.; Koma, A.; Kasamatsu, A.; Hanazawa, T.; Uzawa, K.; et al. Identification of MiR-199-5p and MiR-199-3p Target Genes: Paxillin Facilities Cancer Cell Aggressiveness in Head and Neck Squamous Cell Carcinoma. Genes 2021, 12, 1910. [Google Scholar] [CrossRef] [PubMed]
- Jiang, W.; Xu, Y.; Chen, X.; Pan, S.; Zhu, X. E26 Transformation-Specific Variant 4 as a Tumor Promotor in Human Cancers through Specific Molecular Mechanisms. Mol. Ther. Oncolytics 2021, 22, 518–527. [Google Scholar] [CrossRef]
ETV4-Fusion-Positive (n = 14) | ETV4-Fusion-Negative (n = 86) | p-Value | |
---|---|---|---|
Age | 60.8 ± 6.3 (n = 9) | 61.6 ± 6.1 (n = 68) | 0.653 |
Ethnicity | 0.850 | ||
Asian | 0.0% (0/7) | 4.4% (2/45) | |
African American | 14.3% (1/7) | 13.3% (6/45) | |
White | 85.7% (6/7) | 82.2% (37/45) | |
PSA level | 17.5 ± 25.0 (n = 14) | 14.0 ± 17.0 (n = 82) | 0.626 |
Laterality | 0.703 | ||
bilateral | 92.9% (13/14) | 89.4% (76/85) | |
left | 0.0% (0/14) | 4.7% (4/85) | |
right | 7.1% (1/14) | 5.9% (5/85) | |
Gleason score | 0.398 | ||
6 | 7.1% (1/14) | 9.3% (8/86) | |
7 | 64.3% (9/14) | 54.7% (47/86) | |
8 | 0.0% (0/14) | 11.6% (10/86) | |
9 | 21.4% (3/14) | 23.3% (20/86) | |
10 | 7.1% (1/14) | 1.2% (1/86) | |
M stage | 0.317 | ||
M0 | 92.9% (13/14) | 100.0% (81/81) | |
M1b | 7.1% (1/14) | 0.0% (0/81) | |
T stage | 0.467 | ||
T1c | 40.0% (4/10) | 51.4% (36/70) | |
T2 | 10.0% (1/10) | 1.4% (1/70) | |
T2a | 10.0% (1/10) | 5.7% (4/70) | |
T2b | 10.0% (1/10) | 8.6% (6/70) | |
T2c | 0.0% (0/10) | 15.7% (11/70) | |
T3a | 20.0% (2/10) | 11.4% (8/70) | |
T3b | 10.0% (1/10) | 2.9% (2/70) | |
T4 | 0.0% (0/10) | 2.9% (2/70) |
Gene | Signaling Pathway | Drug |
---|---|---|
TOP1 | Irinotecan pathway Androgen receptor signaling | Irinotecan |
Topotecan, Carboplatin, Cyclophosphamide | ||
HSPA5 | Irinotecan pathway Androgen receptor signaling | Fluorouracil |
NQO1 | Metabolism | Amrubicin |
PARP1 | Androgen receptor signaling | Olaparib |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shin, Y.J.; Yun, J.W.; Kim, H.S. Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion. Biomedicines 2022, 10, 2650. https://doi.org/10.3390/biomedicines10102650
Shin YJ, Yun JW, Kim HS. Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion. Biomedicines. 2022; 10(10):2650. https://doi.org/10.3390/biomedicines10102650
Chicago/Turabian StyleShin, Ye Ji, Jae Won Yun, and Hong Sook Kim. 2022. "Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion" Biomedicines 10, no. 10: 2650. https://doi.org/10.3390/biomedicines10102650